OR WAIT 15 SECS
Lonza announced an endothelial cell application center, which expands Lonza’s support for researchers.
On August 15, 2017, Lonza announced an endothelial cell application center, which expands the company’s support for researchers. The online suite provides scientists with educational materials and product information to assist with endothelial cell research.
The center is accessible online anytime and anywhere and categorized by research area. Features include a comprehensive portal of support resources that are free to download, such as technical whitepapers, research publications, and product information for applications ranging from inflammation and angiogenesis to cardiovascular disease. One-to-one customer support is also provided.
The dysfunction of endothelial cells, which regulate various homeostatic processes within the body, has important implications for diseases including diabetes, cardiovascular disease, and cancer. Increased understanding of these cells aids researchers in the development of effective drug treatments for related diseases. As endothelial cells are particularly hard to co-culture, the support center contains materials that provide direction and address questions on setting up more challenging in vitro cultures, such as for blood-brain barrier modeling and tissue engineering.
The company offers a range of authenticated, ready-to-use human primary endothelial cells. The portfolio contains more than 30 varieties of human primary endothelial cells from tissue sources ranging from heart, lung, and skin, to the reproductive organs, and includes cells from type I and type II diabetic donors.